Tarian Pharma Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC
  • (Upcoming)

  • Latest Deal Amount
  • $16.8M

  • Investors
  • 4

Tarian Pharma General Information

Description

Developer of drugs for dermatology designed to protect cancer patients from severe skin toxicities. The company produces a topical extended-release formulation that induces localized vasoconstriction, is protected by patents covering composition and use, and is being evaluated in multiple phase 2 clinical studies for treatment-related dermatological conditions, enabling oncology care providers to maintain treatment adherence, reduce dose-limiting side effects, and support patient quality of life throughout therapy.

Contact Information

Website
www.tarianpharma.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4 Traverse Dupont
  • 06130 Grasse
  • France
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 4 Traverse Dupont
  • 06130 Grasse
  • France

Tarian Pharma Timeline

20232024202520262027
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tarian Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 01-Jan-2027 $16.8M Upcoming Generating Revenue
5. Accelerator/Incubator 11-Aug-2025 Completed Generating Revenue
4. Later Stage VC 23-Feb-2024 Completed Clinical Trials - Phase 2
3. Seed Round 01-Dec-2022 Completed Clinical Trials - Phase 1
2. Grant 04-Jul-2022 $395K Completed Clinical Trials - General
1. Accelerator/Incubator 16-Feb-2021 Completed Clinical Trials - General
To view Tarian Pharma’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Tarian Pharma Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bpifrance Sovereign Wealth Fund Minority
I-Lab Other
Incubator Provence Côte d'Azur Accelerator/Incubator
InnovaGrasse Accelerator/Incubator
To view Tarian Pharma’s complete investors history, request access »

Ready to get started?

Request a free trial

Tarian Pharma FAQs

  • When was Tarian Pharma founded?

    Tarian Pharma was founded in 2020.

  • Where is Tarian Pharma headquartered?

    Tarian Pharma is headquartered in Grasse, France.

  • What industry is Tarian Pharma in?

    Tarian Pharma’s primary industry is Drug Discovery.

  • Is Tarian Pharma a private or public company?

    Tarian Pharma is a Private company.

  • What is Tarian Pharma’s current revenue?

    The current revenue for Tarian Pharma is .

  • How much funding has Tarian Pharma raised over time?

    Tarian Pharma has raised $3.69M.

  • Who are Tarian Pharma’s investors?

    Bpifrance, I-Lab, Incubator Provence Côte d'Azur, and InnovaGrasse have invested in Tarian Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process